BeiGene
China's largest global biotech company focused on innovative oncology medicines
Signal history
3 totalBeOne Medicines Reports Q4 Revenue of $1.2B, FY Revenue Hits $4.5B
BeOne Medicines announced its fourth quarter and full year 2025 financial results, reporting global success for its drug BRUKINSA and demonstrating foundational oncology leadership. The company highlighted its financial performance and strategic advancements in the oncology sector. This report provides investors and stakeholders with an update on the company's commercial and operational achievements.
BRUKINSA Achieves 74% 6-Year PFS in Chronic Lymphocytic Leukemia
BeiGene announced landmark 6-year progression-free survival (PFS) data for BRUKINSA in patients with treatment-naïve chronic lymphocytic leukemia (CLL). The data showed a 74% PFS rate, representing a significant achievement in the long-term management of CLL. This demonstrates BRUKINSA's sustained efficacy and potential as a foundational therapy for patients with this hematologic malignancy.
BRUKINSA Achieves 74% 6-Year PFS in Treatment-Naïve CLL
BeOne Medicines announced landmark data showing BRUKINSA achieved a 74% 6-year progression-free survival (PFS) rate in patients with treatment-naïve chronic lymphocytic leukemia (CLL). These results, presented at ASH 2025, underscore BRUKINSA's long-term efficacy and durability as a foundational treatment for CLL, reinforcing its position in the market.
Key Changes (30d)
BRUKINSA Delivers Landmark 74% 6-Year PFS in Chronic Lymphocytic Leukemia
BeiGene announced that BRUKINSA achieved a 74% 6-year progression-free survival rate in treatment-naïve chronic lymphocytic leukemia patients.
BRUKINSA Demonstrates Strong 6-Year PFS in Treatment-Naïve CLL Patients
BRUKINSA demonstrated a 74% 6-year progression-free survival rate in treatment-naïve CLL patients, reinforcing its efficacy as a foundational therapy.
BeOne Medicines Reports Q4 and FY 2025 Financials, Highlighting BRUKINSA Success
BeOne Medicines reports Q4 revenue of $1.2B (+20% YoY) and FY2025 revenue of $4.5B (+18% YoY), driven by BRUKINSA success.
Source Language Distribution
Strategic themes and signal pattern
Strategic Themes
Recent Signal Pattern
Industry Peer Comparison
Why this company matters
BeiGene has shattered the perception that Chinese biotech companies cannot compete globally, with Brukinsa becoming a blockbuster drug in the US and European markets.
- Key domain relevance: Oncology, Hematology, Immunology
- Active monitoring with 3 signals in the last 30 days across 6 tracked sources.
Channel Context
BeiGene is a key company within the Healthtech & Biotech channel. Its official updates regularly contribute to how users track developments in this space.
View channelMarket Context
This company operates in one of SigFact's strongest advantage markets, where official updates often surface first in local language.
See recent signals in this marketPeers and related companies
All companiesAstellas Pharma
Adv. marketMajor Japanese pharma company focused on urology, oncology, and transplantation
AstraZeneca
Anglo-Swedish pharma company with strong oncology and rare disease pipeline
Biocon
India's largest biopharmaceutical company and global biosimilars leader
Biofourmis
Digital therapeutics and remote patient monitoring platform
CSL Limited
Global biotech leader in plasma-derived therapies and vaccines
Celltrion
Adv. marketSouth Korea's leading biosimilar manufacturer challenging global pharma giants
Continue monitoring BeiGene
Follow this company, add it to your watchlist, or explore its signal stream to stay informed.